Comparing two imaging scans for finding multiple myeloma lesions
Compares two PET scan tracers for detecting multiple myeloma lesions in adults.
Plain-language title generated from the registry record
Registry title: FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)
Key facts
- Where
- Besancon Cedex and Dijon, FranceSee the 3 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT04349358, who can take part
Where in France
- CHU BesanconBesancon Cedex, FranceNo longer taking part
- Centr Georges Francois LeclercDijon, FranceNo longer taking part
- Centre Hospitalier Universitaire de DijonDijon, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Georges Francois Leclerc
- Trial code
- NCT04349358EU 2024-516682-36-00
- Record updated
- 17 October 2023
- Original description
Hybrid positron emission tomography/computed tomography (PET/CT) has now become available to detect tumors in patients with multiple myeloma. The radioactive glucose 18F-fluorodeoxyglucose (FDG) is the most widely used tracer but findings suggest that PET/CT reveal more lesions when using FCH.Read full original descriptionShow less
18F-Fluorocholine (FCH) Versus 18F-Fluorodesoxyglucose (FDG) PET/CT in Detection of Lesions in Patients With Multiple Myeloma
Hybrid positron emission tomography/computed tomography (PET/CT) has now become available to detect tumors in patients with multiple myeloma. The radioactive glucose 18F-fluorodeoxyglucose (FDG) is the most widely used tracer but findings suggest that PET/CT reveal more lesions when using FCH.
In this study, FDG is compared with a more recent metabolic tracer, 18F-fluorocholine (FCH), for the detection of multiple myeloma lesions at time of initial extension assessment.
The principal objective of this sudy is to compare the number of suspected hypermetabolic foci of myeloma detected by 18F-fluorocholine PET and by 18F-fluorodeoxyglucose PET during the initial extension assessment.
Inclusion: Patient with initial diagnosis of multiple myeloma has just been established; Therapeutic indication and eligible for a HSC autograft (if the HSC autograft could not be performed, the patient will still be retained in the study); Status ECOG 0, 1 or 2; Age ≥ 18 and < 75 ans years; Effective contraception for women; Informed consent signed; Patient able to lie flat for 30 minutes; Patient affiliated to a social security scheme.
Exclusion: Patient with concomitant neoplasia; Patient treated with long-term corticosteroids; Patient being treated with hematopoietic growth factors; Patient with a history of hematological or solid neoplasia, except if it is a basal cell carcinoma of the skin or an adenocarcinoma in situ of the uterine cervix; Patient with a history of sarcoidosis; Uncontrolled diabetes; History of allergic reaction attributed to 18F-fluorodeoxyglucose or to 18F-fluorocholine; Patient diagnosed with a diagnosis of MGUS (Monoclonal Gammapathy of Undetermined Significance = monoclonal gammopathy of undetermined significance), indolent myeloma ("smoldering myeloma"), non-secreting myeloma or recurrent myeloma,; Patient already under treatment for myeloma; Patient not eligible for intensive treatment followed by a HSC autograft; Patient in sepsis; Claustrophobic patient; Refusal of patient consent; Pregnant or lactating woman; Women of childbearing potential without effective contraception; Person deprived of liberty or under guardianship; Impossibility to submit to the medical follow-up of the trial for geographic, social or psychological reasons.